On November 5, 2026, the U.S. Food and Drug Administration granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for certain adults with head and neck squamous cell carcinoma, or HNSCC. The Rybrevant Faspro approval applies to recurrent or metastatic disease that has progressed on or after platinum-based chemotherapy and immunotherapy.
The decision provides another treatment option for a defined group of patients, but it does not establish that the medicine improves long-term outcomes. The FDA requires confirmatory studies to verify and describe its clinical benefit.
Who the Rybrevant Faspro approval covers
According to the FDA’s approval announcement, the indication is for adults whose HNSCC has returned or spread and whose disease has progressed on or after both platinum-based chemotherapy and immunotherapy. It is not a general approval for every person with head and neck cancer.
The FDA specifically states that Rybrevant Faspro is not indicated for patients with oropharyngeal squamous cell carcinoma associated with human papillomavirus, or HPV. That exclusion is important when discussing whether the newly approved indication matches someone’s cancer diagnosis.
The announcement is particularly relevant to patients and caregivers reviewing options after those prior treatments. The FDA describes HNSCC as an aggressive, life-threatening disease with a high unmet need for effective therapies.
What the clinical trial found
The approval was based on an open-label, multicenter clinical trial involving 102 patients with recurrent or metastatic HNSCC. The overall response rate was 42%. In the announcement, a response meant that a patient’s tumor decreased in size or disappeared.
Among the patients who responded, 56% had a response lasting at least six months. That percentage refers to responders, not to all 102 trial participants.
The FDA said currently approved therapies have overall response rates of around 20% or less. However, the announcement does not describe a randomized, head-to-head comparison between Rybrevant Faspro and those therapies. The reported percentages should not be read as proof that an individual patient will have a better outcome with this medicine.
What accelerated approval does—and does not—mean
The FDA’s Accelerated Approval Program allows earlier approval of medicines for serious conditions with unmet medical needs. These decisions can rely on surrogate or intermediate endpoints rather than confirmed long-term clinical outcomes.
For Rybrevant Faspro, the supporting endpoints were overall response rate and duration of response: how many patients’ tumors shrank or disappeared, and how long those responses lasted.
The FDA says it is not yet confirmed whether these findings will translate into a clinically meaningful benefit in long-term outcomes. Confirmatory studies are therefore required. Tumor response is the basis for this approval, not proof of longer survival or a cure.
Safety warnings and discussion with the oncology team
The prescribing information for Rybrevant Faspro as a single agent includes warnings and precautions for hypersensitivity and administration-related reactions; interstitial lung disease or pneumonitis; dermatologic adverse reactions; ocular toxicity; and harm to an unborn baby.
In plain language, these warnings concern allergic and administration-related reactions, lung inflammation, skin reactions, eye toxicity, and pregnancy-related risk. The announcement does not provide individual risk estimates or detailed instructions for managing these problems.
Patients considering this option should discuss the approved eligibility criteria, expected benefits, uncertainties, and safety warnings with their oncology team. Whether it is appropriate requires a professional review of the cancer diagnosis and previous treatment history; this announcement alone cannot determine an individual treatment choice.
Frequently Asked Questions
Is Rybrevant Faspro approved for all head and neck cancers?
No. This indication covers certain adults with recurrent or metastatic HNSCC after disease progression on or after platinum-based chemotherapy and immunotherapy. It excludes HPV-associated oropharyngeal squamous cell carcinoma.
Does the 42% response rate mean the medicine cures cancer?
No. It means tumors shrank or disappeared in 42% of trial participants. The FDA has not confirmed a clinically meaningful benefit in long-term outcomes.
Why are more studies required after approval?
The FDA granted accelerated approval based on response rate and response duration. Confirmatory studies must verify and describe the medicine’s clinical benefit.
